All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
Formulary
Back
Contact us about this page
Chapter 2: Cardiovascular
Toggle Pages
Print this page
Management of atrial fibrillation
Management of other arrhythmias
Drugs that prolong the QT interval
Anticoagulation prescribing guidance
Management of suspected deep vein thrombosis (DVT) and pulmonary embolism (PE)
Secondary prevention of stroke / TIA
Management of angina
Chronic heart failure guidance
Management of hypertension
Management of blood lipids
2.1 Positive inotropic drugs
2.2 Diuretics
2.3 Anti-arrhythmic drugs
2.4 Beta-adrenoceptor blocking drugs
2.5 Hypertension and heart failure
2.6 Nitrates, calcium-channel blockers, and other antianginal drugs
2.7 Sympathomimetics
2.8 Anticoagulants and protamine
2.9 Antiplatelet drugs
2.10 Stable angina, acute coronary syndromes, and fibrinolysis
2.11 Antifibrinolytic drugs and haemostatics
2.12 Lipid-regulating drugs
2.14 Miscellaneous cardiovascular preparations
Page last updated:
16 November 2023
Contact us about this page
2.14 Miscellaneous cardiovascular preparations
First Line
Second Line
Specialist
Hospital Only
Myosin Inhibitors
Mavacamten
- Capsules 2.5mg, 5mg, 10mg, 15mg
Notes
- NICE TA913: Mavacamten (Camzyos) is recommended as an option for treating symptomatic obstructive hypertrophic cardiomyopathy in adults who have a New York Heart Association class of 2 to 3 (September 2023), only if:
- it is an add-on to individually optimised standard care that includes beta-blockers, non-dihydropyridine calcium-channel blockers or disopyramide, unless these are contraindicated, and
- the company provides it according to the commercial arrangement.
